Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing

Author(s):  Allen Loyd V Jr

Issue:  Mar/Apr 2018 - Volume 22, Number 2
View All Articles in Issue

Page(s):  92

PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing Page 1

Download in electronic PDF format for $75

Abstract:  

Related Keywords: DQSA, U.S. House of Representatives Energy and Commerce Committee, Subcommittee on Health, Examining Implementation of the Compounding Quality Act, U.S. Food and Drug Administration, FDA, pharmacy compounding oversight and regulation, office-use compounding, Pharmacy Compounding Advisory Committee, PCAC, dietary supplements, CGMP standards, Guidance for Industry documents, HR2871

Related Categories: LEGAL, PROFESSIONAL ISSUES

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing
Allen Loyd V Jr
Mar/Apr 2018
Pg. 92

IACP Legislative/Regulatory Update: The International Academy of Compounding Pharmacists Testifies at U.S. House of Representatives' Energy & Commerce Health Subcommittee Pharmacy Compounding Hearing
Blankenship Cynthia
Mar/Apr 2018
Pg. 125-126

Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
Jul/Aug 2016
Pg. 351

View Sample
Standing Together Fixing the Drug Quality and Security Act
Miller David G
Mar/Apr 2015
Pg. 104-106

U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
Nov/Dec 2015
Pg. 487-488

PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Allen Loyd V Jr
Sep/Oct 2015
Pg. 389-390

U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013
Miller David G
Jan/Feb 2014
Pg. 35-36

U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Miller David G
Jul/Aug 2015
Pg. 303-305

U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)
Nov/Dec 2016
Pg. 457-458

Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration
Kupiec Tom
, Kemp Jesse
Jul/Aug 2007
Pg. 326-327

Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
Jul/Aug 2020
Pg. 296-297

Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA
Cabaleiro Joe
Sep/Oct 2021
Pg. 358-362

U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Snow Stephen T
, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Jan/Feb 2019
Pg. 32-33

PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 1
Allen Loyd V Jr
Jul/Aug 2007
Pg. 350-351

The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Miller David G
May/Jun 2014
Pg. 208

U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Yoch Doug
Mar/Apr 2017
Pg. 95-102

Applying Quality of Design Concepts to Pharmacy Compounding
Timko Robert J
Nov/Dec 2015
Pg. 453-463

The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Brunner Scott
Jan/Feb 2023
Pg. 22-23

The Evolution of 21 CFR Parts 210 & 211 for Drug Compounders: An Unspoken Opportunity for Pharmacists
Parks Kenneth Chase
, Bernard Brian, Cogdill Christopher Blake
Sep/Oct 2015
Pg. 377-380

Return to Top